PL Lodz Watala C: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|city=Lodz | |city=Lodz | ||
|country=Poland | |country=Poland | ||
|MiPNetLab=Watala C, Labieniec M | |MiPNetLab=Watala C, Labieniec M, Siewiera K | ||
|info=[http://www.oroboros.at/?IOC55-56 IOC55-56], [[IOC61]] | |info=[http://www.oroboros.at/?IOC55-56 IOC55-56], [[IOC61]] | ||
}} | }} | ||
Revision as of 16:55, 3 June 2012
- Mitochondrial respiratory capacity nder normal and pathophysiological conditions (diabetes mellitu, atherothrombosis, brain-blood barrier disruption, cancerogenesis)
- Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity
- targeting of biochemical and molecular burden of diabetes
